Holen Sie sich die Stockscreener-App
12.18
0.83%
0.10
Schlusskurs vom Vortag:
$12.08
Offen:
$11.94
24-Stunden-Volumen:
3.42M
Relative Volume:
1.38
Marktkapitalisierung:
$1.24B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-2.2308
EPS:
-5.46
Netto-Cashflow:
$-382.65M
1W Leistung:
-5.58%
1M Leistung:
-7.16%
6M Leistung:
-49.57%
1J Leistung:
-58.88%
1-Tages-Spanne:
$11.85
$12.45
1-Wochen-Bereich:
$11.79
$13.79
52-Wochen-Spanne:
$11.79
$34.87
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.18 | 1.24B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Cathie Wood's ARK buys Intellia, sells Tesla in latest stock trades - Investing.com
Intellia Crashes 60% in a Year: How Should You Play the Stock? - Nasdaq
First Week of February 2025 Options Trading For Intellia Therapeutics (NTLA) - Nasdaq
Barclays PLC Buys 44,022 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowHere's What Happened - MarketBeat
3 Things You Need to Know if You Buy CRISPR Therapeutics Today - AOL
State Street Corp Raises Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
(NTLA) Proactive Strategies - Stock Traders Daily
Intellia Therapeutics' SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics' SWOT analysis: gene editing stock faces pivotal year By Investing.com - Investing.com UK
Short Interest in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Rises By 15.5% - MarketBeat
Wellington Management Group LLP Has $13.25 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 4.2%Here's What Happened - MarketBeat
Intellia stock touches 52-week low at $12.81 amid biotech slump - Investing.com
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent - BioSpace
Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Intellia Not Entitled to 'Safe Harbor' in BlueAllele Patent Suit - Bloomberg Law
Intellia Can't Escape Patent Suit Over $100M Regeneron Deal - Law360
Two Sigma Advisers LP Buys 257,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 52,297 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Fmr LLC - MarketBeat
Charles Schwab Investment Management Inc. Acquires 37,714 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.5%Time to Buy? - MarketBeat
Benjamin Edwards Inc. Has $1.19 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Verition Fund Management LLC Purchases 50,763 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
(NTLA) Investment Analysis - Stock Traders Daily
Shareholders in Intellia Therapeutics (NASDAQ:NTLA) have lost 88%, as stock drops 4.7% this past week - Simply Wall St
Future-Proofing Growth of Gene Editing Technology Innovation - openPR
Patient Square Capital LP Invests $2.64 Million in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Chevy Chase Trust Holdings LLC Sells 231,592 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
PDT Partners LLC Reduces Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
BNP Paribas Financial Markets Has $5.06 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Awards Key Executive Inducement Grant with 3-Year Vesting Schedule | NTLA Stock News - StockTitan
CRISPR Technology Market Growth Trends from 2024 to 2033 | Key - openPR
Intellia Therapeutics Announces Promising CRISPR Therapy Results - TipRanks
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy - MSN
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Intellia Therapeutics' SWOT analysis: gene editing firm's stock faces pivotal trials - Investing.com
Gene-editing therapy aiding FAP patients year or more later: Trial - FAP News Today
Hereditary Angioedema Market Expected to Experience Major - openPR
Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks - 2 Minute Medicine
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - The Manila Times
Intellia's CRISPR Therapy Nex-Z Secures FDA RMAT Designation for Rare Disease Treatment | NTLA Stock News - StockTitan
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? - sharewise
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
Equities Analysts Offer Predictions for NTLA FY2025 Earnings - MarketBeat
Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - MSN
This Beaten-Down Stock Could Soar by 354%, According to Wall Street - AOL
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '24 |
Sale |
22.93 |
405 |
9,287 |
71,470 |
| Verwiel Frank | Director |
Jun 17 '24 |
Sale |
25.00 |
1,505 |
37,625 |
17,948 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '24 |
Sale |
32.99 |
2,297 |
75,778 |
81,571 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '24 |
Sale |
32.99 |
605 |
19,959 |
71,470 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 08 '24 |
Sale |
28.87 |
2,275 |
65,682 |
43,927 |
| LEONARD JOHN M | President and CEO |
Jan 03 '24 |
Sale |
29.46 |
19,223 |
566,310 |
846,486 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '24 |
Sale |
29.46 |
5,843 |
172,135 |
54,372 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '24 |
Sale |
29.46 |
5,532 |
162,973 |
46,202 |
| Goddard Glenn | EVP, Chief Financial Officer |
Jan 03 '24 |
Sale |
29.46 |
5,365 |
158,053 |
40,585 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '24 |
Sale |
29.46 |
3,877 |
114,216 |
36,987 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):